Literature DB >> 2185723

A randomized placebo-controlled trial of cysteamine eye drops in nephropathic cystinosis.

M I Kaiser-Kupfer1, M A Gazzo, M B Datiles, R C Caruso, E M Kuehl, W A Gahl.   

Abstract

Eighteen patients with nephropathic cystinosis who were younger than 42 months and 11 patients 4 to 31 years of age were entered into a double-masked, randomized, placebo-controlled trial of topical cysteamine eye drops between November 1985 and September 1989. Eight of the younger patients and 2 of the older patients showed marked clearing of corneal crystals in one eye compared with the fellow eye. When the code was broken, all 10 patients were found to have received cysteamine eye drops in the improved eye. Of the remaining 19 patients 4 were unavailable for follow-up. In 15 patients no marked difference was noted between the two eyes. Eight have presumably been in the protocol for too short a time and several have been poor compliers with the therapy. These results not only demonstrate the potential for primary prevention of corneal crystal deposition but also, for the first time, offer the possibility of reversing the corneal complications of cystinosis in older patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2185723     DOI: 10.1001/archopht.1990.01070070075038

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  19 in total

1.  Evaluation of topical cysteamine therapy in the CTNS(-/-) knockout mouse using in vivo confocal microscopy.

Authors:  Jennifer L Simpson; Chyong Jy Nien; Kevin J Flynn; James V Jester
Journal:  Mol Vis       Date:  2011-10-08       Impact factor: 2.367

2.  Clearance of corneal crystals in nephropathic cystinosis by topical cysteamine 0.5%.

Authors:  N P Jones; R J Postlethwaite; J L Noble
Journal:  Br J Ophthalmol       Date:  1991-05       Impact factor: 4.638

3.  A multicentre randomised double masked clinical trial of a new formulation of topical cysteamine for the treatment of corneal cystine crystals in cystinosis.

Authors:  E T Tsilou; D Thompson; A S Lindblad; G F Reed; B Rubin; W Gahl; J Thoene; M Del Monte; J A Schneider; D B Granet; M I Kaiser-Kupfer
Journal:  Br J Ophthalmol       Date:  2003-01       Impact factor: 4.638

Review 4.  Ophthalmic manifestations and histopathology of infantile nephropathic cystinosis: report of a case and review of the literature.

Authors:  Ekaterini Tsilou; Min Zhou; William Gahl; Pamela C Sieving; Chi-Chao Chan
Journal:  Surv Ophthalmol       Date:  2007 Jan-Feb       Impact factor: 6.048

Review 5.  The renal Fanconi syndrome in cystinosis: pathogenic insights and therapeutic perspectives.

Authors:  Stephanie Cherqui; Pierre J Courtoy
Journal:  Nat Rev Nephrol       Date:  2016-12-19       Impact factor: 28.314

6.  Effect of Storage Conditions on Stability of Ophthalmological Compounded Cysteamine Eye Drops.

Authors:  Ahmed Reda; Ann Van Schepdael; Erwin Adams; Prasanta Paul; David Devolder; Mohamed A Elmonem; Koenraad Veys; Ingele Casteels; Lambertus van den Heuvel; Elena Levtchenko
Journal:  JIMD Rep       Date:  2017-12-07

Review 7.  Nephropathic cystinosis: late complications of a multisystemic disease.

Authors:  Galina Nesterova; William Gahl
Journal:  Pediatr Nephrol       Date:  2008-06       Impact factor: 3.714

8.  Treatment of Inherited Eye Defects by Systemic Hematopoietic Stem Cell Transplantation.

Authors:  Celine J Rocca; Alexander Kreymerman; Sarah N Ur; Katie E Frizzi; Swati Naphade; Athena Lau; Tammy Tran; Nigel A Calcutt; Jeffrey L Goldberg; Stephanie Cherqui
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-11       Impact factor: 4.799

Review 9.  Early oral cysteamine therapy for nephropathic cystinosis.

Authors:  William A Gahl
Journal:  Eur J Pediatr       Date:  2003-11-11       Impact factor: 3.183

Review 10.  Drug treatment of inborn errors of metabolism: a systematic review.

Authors:  Majid Alfadhel; Khalid Al-Thihli; Hiba Moubayed; Wafaa Eyaid; Majed Al-Jeraisy
Journal:  Arch Dis Child       Date:  2013-03-26       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.